Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma

James E. Fish, Jill P. Karpel, Timothy J. Craig, George W. Bensch, Michael Noonan, D. Robert Webb, Bernard Silverman, Eric J. Schenkel, Anthony R. Rooklin, Joe W. Ramsdell, Robert Nathan, Jeffrey G. Leflein, Jay Grossman, David F. Graft, Richard G. Gower, Stuart M. Garay, Evangelo Frigas, Arthur C. DeGraff, Edwin A. Bronsky, David I. BernsteinWilliam Berger, Lucy Shneyer, Keith B. Nolop, Judy E. Harrison

Research output: Contribution to journalArticle

59 Scopus citations

Abstract

Background: Inhaled corticosteroid therapy in severe persistent asthma has been shown to reduce or eliminate oral corticosteroid (OCS) use while retaining effective asthma control. Objective: We sought to evaluate the ability of mometasone furoate (MF) delivered by means of dry powder inhaler to reduce daily oral prednisone requirements in OCS-dependent patients with severe persistent asthma. Methods: We performed a 12-week, double-blind, placebo-controlled trial (21 centers, 132 patients) comparing 2 doses of MF (400 and 800 μg administered twice daily) with placebo, followed by a 9-month open-label phase in which 128 patients received treatment with MF. Results: At the endpoint of the double-blind trial, MF 400 and 800 mg twice daily reduced daily OCS requirements by 46.0% and 23.9%, respectively, whereas placebo increased OCS requirements by 164.4% (P < .01). Oral steroids were eliminated in 40%, 37%, and 0% of patients in the MF 400 and 800 mg twice daily and placebo groups, respectively. Pulmonary function and quality of life significantly increased for MF-treated patients. Further reductions in OCS requirements were achieved with long-term MF treatment in the open-label phase. Conclusion: MF inhaled orally as a dry powder is an effective alternative to systemic corticosteroids in patients with severe persistent asthma.

Original languageEnglish (US)
Pages (from-to)852-860
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Volume106
Issue number5
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Keywords

  • Glucocorticoid
  • Health-related quality of life
  • Mometasone furoate
  • Oral corticosteroid-dependent asthma
  • Prednisone
  • Severe persistent asthma
  • Steroid sparing

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma'. Together they form a unique fingerprint.

  • Cite this

    Fish, J. E., Karpel, J. P., Craig, T. J., Bensch, G. W., Noonan, M., Webb, D. R., Silverman, B., Schenkel, E. J., Rooklin, A. R., Ramsdell, J. W., Nathan, R., Leflein, J. G., Grossman, J., Graft, D. F., Gower, R. G., Garay, S. M., Frigas, E., DeGraff, A. C., Bronsky, E. A., ... Harrison, J. E. (2000). Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma. Journal of Allergy and Clinical Immunology, 106(5), 852-860. https://doi.org/10.1067/mai.2000.110798